glp-1-based treatments approved for weight loss 2025 Weight-loss drugs such as Ozempic were in the headlines a lot in – and patent protections these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ List of approved and pending

Lo S-C, Li X, Henzl MT, Beamer LJ, Hannink M

In real-world observations, individuals on GLP-1 therapies often fall below dietary benchmarks for: 3,5 Microminerals : magnesium, potassium, calcium, iron, and zinc Vitamins : D, A, E, K, B12, B1 (thiamine), and folate Macronutrients : protein and fiber Phytonutrients : including carotenoids and flavonoids Gastrointestinal effectsincluding nausea, bloating, early satiety, and evolving food aversionsfurther constrict intake variety and volume, amplifying the risk

GLP-1 drugs (glucagon-like peptide-1 receptor agonists) are medications developed to treat both type 2 diabetes and obesity by correcting hormonal imbalance - stimulating insulin release and suppressing excess glucagon -to bring blood sugar back under control

doi:10.1016/j.phrs.2023.107031 192